Pedersen COPENHAGEN (Reuters) -Shares in Novo Nordisk rose on Monday after the Wegovy maker lost out to Pfizer in a $10 billion bidding war for U.S. biotech Metsera, as investors had viewed its offer as too complex.

Trump announces deal with Eli Lilly, Novo Nordisk to lower cost of GLP-1 weight loss drugs Wegovy, Zepbound. Here's what to know and Medicare coverage

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year forecasts on Wednesday as sales growth of its blockbuster obesity drugs slows, leaving investors worried the firm is losing ground to U.

Novo Nordisk’s oral therapy Wegovy (semaglutide) reduced cardiovascular risk factors in the Phase III OASIS 4 trial. Being used by the company to support the drug's approval in obesity, the study led to greater improvements in risk factors such as C-reactive protein and serum triglycerides.

The White House is nearing an agreement with pharmaceutical companies Novo Nordisk and Eli Lilly to offer some of their weight loss drugs at a lower price through Trump Rx, a source familiar confirmed to ABC News. Under the pending agreements, a month's supply of the drugs will cost roughly $149, the source added.

Hims & Hers continues to sell compounded semaglutide, the active ingredient in Novo’s Wegovy and Ozempic drugs, and these generic versions are more affordable than the branded drugs. The company also recently rolled out compounded GLP-1 microdosing treatment plans.

Novo Nordisk navigates competition and guidance challenges with strong profitability and upcoming oral Wegovy opportunities. Learn why NVO stock is a buy.

Novo Nordisk’s oral semaglutide 25 mg achieved up to 16.6% weight loss in a landmark study, rivaling injectable Wegovy. The pill also improved cardiovascular risk factors and physical activity levels.

President Donald Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to reduce prices for their obesity treatments Zepbound and Wegovy. Here’s what we know.